Ad
related to: is aficamten fda approved
Search results
Results from the WOW.Com Content Network
Aficamten (CK-274) is a cardiac myosin inhibitor [1] developed by Cytokinetics for the treatment of obstructive hypertrophic cardiomyopathy. [2] [3] [4] References
Aficamten received Breakthrough Therapy Designation for the treatment of symptomatic obstructive HCM from the U.S. Food & Drug Administration (FDA) as well as the National Medical Products Administration (NMPA) in China. Cytokinetics submitted a New Drug Application (NDA) to the FDA in Q3 2024 and expects to submit a Marketing Authorization ...
In July 2020, Ji Xing Pharmaceuticals signed a financing deal with Cytokinetics, which included the rights to commercialize the drug designed to treat hypertrophic cardiomyopathies, aficamten, in China and certain neighboring regions. [9]
The presentations included an integrated safety analysis from three clinical studies of aficamten and an analysis of the withdrawal of standard of care medications in patients treated with aficamten in FOREST-HCM (Follow-up, Open-Label, Research Evaluation of Sustained Treatment with Aficamten in HCM), the open label extension clinical study of ...
Main page; Contents; Current events; Random article; About Wikipedia; Contact us
Aficamten has tested very well in clinical trials and, as such, has vast potential, especially in a massive market like China. Don’t miss this second chance at a potentially lucrative opportunity
No reduction in the secondary endpoint of time to cardiovascular death was observed. In general, the overall rates of myocardial ischemia, ventricular arrhythmias, and death were similar between treatment and placebo groups. Adverse events and treatment discontinuation of study drug were balanced between treatment arms.
Just because the FDA approves a drug doesn’t necessarily mean that Medicare will pay for it for all patients. Before Leqembi was approved, another similar medication was approved called Aduhelm.
Ad
related to: is aficamten fda approved